Zimmer Biomet sets quarterly dividend at $0.24 per share

WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a global leader in medical technology, has declared a quarterly cash dividend for the second quarter of 2025. The company’s Board of Directors announced that stockholders would receive a dividend of $0.24 per share, which is scheduled to be paid on July 31, 2025, to those on record as of June 26, 2025. According to InvestingPro data, the company has maintained dividend payments for 14 consecutive years, with a current annual dividend yield of 1.03%.

This dividend payment reflects Zimmer Biomet’s ongoing commitment to providing value to its shareholders. The company, with a history spanning over 90 years and a market capitalization of $18.47 billion, has built a reputation for delivering high-quality solutions in the medical technology sector. With a robust gross profit margin of 71.2% and strong liquidity indicated by a current ratio of 2.44, Zimmer Biomet operates in more than 25 countries and markets its products in over 100 countries, emphasizing the importance of innovation and digital integration in its product offerings. InvestingPro analysis reveals several more key metrics and insights available to subscribers.

Zimmer Biomet’s portfolio includes a wide range of medical devices and solutions designed to enhance patient mobility and improve health outcomes. The company has been at the forefront of integrating digital and robotic technologies into its products, leveraging data analytics and artificial intelligence to transform the patient experience.

The announcement of the dividend is based on a press release statement from Zimmer Biomet Holdings, Inc. The company’s commitment to its stockholders is part of its broader mission to evolve and innovate within the healthcare industry, ensuring the delivery of the highest quality solutions to patients and providers alike.

Investors in Zimmer Biomet can view this dividend payment as part of the company’s financial strategy, reflecting its stable position in the market and its ability to generate shareholder returns. As the payment date approaches, stockholders of record by the close of business on June 26, 2025, will be eligible to receive the declared dividend.

In other recent news, Zimmer Biomet reported a first-quarter sales figure of $1.91 billion, marking a 2.3% growth on a constant currency basis, slightly exceeding Wall Street’s expectations. The company’s adjusted earnings per share (EPS) stood at $1.81, surpassing consensus estimates by 2.5%. However, analysts have expressed concerns about Zimmer Biomet’s future outlook, leading to several adjustments in stock targets. Bernstein SocGen reduced its price target to $100, citing potential risks from sales reorganization and tariffs, while maintaining a Market Perform rating. TD Cowen also lowered its target to $104, highlighting uncertainties related to tariffs and future performance. UBS maintained a Sell rating with a $105 target, noting the company’s modest revenue outperformance but expressing caution about new product launches and market share gains. Morgan Stanley further reduced the price target to $95, pointing to underperformance in the U.S. Knee business and potential impacts from tariffs expected in 2026. Additionally, Zimmer Biomet announced the appointment of Kevin Thornal as the new Group President for the Americas, effective July 1, 2025, as part of its strategic leadership changes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.